Lisdexamfetamine Dimesylate Capsule
Product Images NDC 72162-2451

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Lisdexamfetamine Dimesylate (NDC 72162-2451). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl721622451)

Label for Lisdexamfetamine Dimesylate Capsules 10 mg, a prescription oral capsule. The label indicates a package size of 100 capsules. It is relabeled by Bryant Ranch Prepack, Inc. of Burbank, CA, and manufactured by Purdue Pharma L.P. Storage instructions and QR codes for dosage information and package insert are also shown.*

FDA Label Image

Chemical Structure (Lisdexcaps 01)

Chemical structure of lisdexamfetamine dimesylate, depicting the molecular formula with amino groups, a phenyl ring, and dimesylate ions (CH3SO3H)2 as shown in the diagram.*

FDA Label Image

Figure 1 (Lisdexcaps 02)

A chart displaying pharmacokinetic (PK) fold changes and 90% confidence intervals (CI) for LISDEXAMFETAMINE DIMESYLATE across special populations, including gender (male/female), two age groups (65-74 years and 75+ years), varying degrees of renal impairment (mild, moderate, severe), and end stage renal disease. The chart compares Cmax and AUC values showing changes relative to a reference baseline.*

FDA Label Image

Figure 2 (Lisdexcaps 03)

A forest plot chart depicting fold change and 90% confidence intervals for pharmacokinetic parameters Cmax and AUC. The chart compares changes relative to reference values for the drugs Guanfacine, Venlafaxine, and Omeprazole. The x-axis represents change relative to reference from 0.0 to 2.0.*

FDA Label Image

Figure 3 (Lisdexcaps 04)

A forest plot chart comparing the pharmacokinetic (PK) fold change and 90% confidence interval (CI) for various interacting drugs relative to a reference. The chart shows Cmax and AUC values for drugs including Guanfacine, Venlafaxine, caffeine, dextromethorphan, omeprazole, and midazolam, with fold changes on the x-axis ranging from 0.0 to 2.0.*

FDA Label Image

Figure 4 (Lisdexcaps 05)

A line graph comparing LS mean SKAMP deportment scores over time post-dose between Lisdexamfetamine and Placebo groups. The x-axis represents time in hours from -0.5 to 13 hours post-dose, and the y-axis shows scores from 0.0 to 1.9. The graph includes error bars for variability and a legend identifying the two groups.*

FDA Label Image

Figure 5 (Lisdexcaps 06)

A line graph comparing the proportion of subjects with relapse or treatment failure over time (days after randomization) between lisdexamfetamine and placebo groups. The y-axis shows the percentage of subjects with relapse or treatment failure, and the x-axis represents time in days. The lisdexamfetamine group shows a lower proportion of relapse compared to the placebo group, which demonstrates a higher and increasing relapse rate over time.*

FDA Label Image

Figure 6 (Lisdexcaps 07)

A line graph showing LS Mean (SE) PERMP Total Scores over time post-dose (hours) comparing Lisdexamfetamine and placebo. The x-axis represents time from -0.5 to 14 hours after dosing, and the y-axis shows scores ranging approximately from 250 to 330. Lisdexamfetamine scores increase and remain higher than placebo scores throughout the 14-hour period, with error bars indicating standard errors.*

FDA Label Image

Figure 7 (Lisdexcaps 08)

A line chart comparing the proportion of subjects with relapse or treatment failure (%) over time (days after randomization) between placebo and lisdexamfetamine groups. The vertical axis shows the percentage of subjects, and the horizontal axis shows days up to 40. The lisdexamfetamine group shows a substantially lower proportion of relapse/treatment failure over time compared to placebo.*

FDA Label Image

Figure 8 (Lisdexcaps 09)

A line graph comparing the proportion of subjects with relapse over time (days after randomization) between Lisdexamfetamine and placebo groups. The graph shows a solid line for Lisdexamfetamine and a dashed line for placebo, with corresponding subject counts at risk displayed below the x-axis.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.